KKR closed an all-cash take-private of Integer Holdings for $5.7 billion on Monday, pulling the Plano-based medical device contract manufacturer off public markets in the largest medtech outsourcing deal since Carlyle's Cardinal Health battery unit carve-out in 2018. Integer supplies the componentry—batteries, enclosures, neuromodulation leads—that go inside devices sold by Boston Scientific, Abbott, and Medtronic. The deal values Integer at $135 per share, a 34% premium to the 30-day trailing average, and includes assumption of roughly $1.1 billion in net debt.
Integer reported $1.54 billion in trailing twelve-month revenue as of Q2 2025, up 8% year-over-year, with 78% of sales tied to cardiac rhythm management and neuromodulation. Gross margin sat at 28.4%, inline with peers like Sanmina and Benchmark Electronics, but Integer's exposure to high-barrier medical certifications (ISO 13485, FDA QSR) and customer lock-in gave it pricing power that KKR's healthcare infrastructure team flagged in diligence. The firm had been public since 2011, spun out from Greatbatch Ltd., and quietly built a 62% market share in implantable battery enclosures by 2024. KKR's tender offer opens this week and is expected to close in Q4 2025, subject to Hart-Scott-Rodino clearance and a majority shareholder vote.
This is a capacity play disguised as a medtech deal. Integer owns the production knowhow for components that require 18-24 month qualification cycles, $40-60 million cleanroom build-outs, and deep IP around hermetic sealing and miniaturization. As GLP-1 drugs shrink the addressable population for metabolic implants, the outsourcing model gains—OEMs like Medtronic would rather shed fixed costs than build incremental capacity for a flattening market. KKR is betting that Integer's $340 million in annual EBITDA (roughly 22% margin) expands as customers consolidate vendor relationships and as neuromodulation for psychiatric indications scales from $800 million in 2025 to an estimated $3.2 billion by 2030. The firm also sees arbitrage in Integer's underinvestment in automation; the company still runs 43% manual assembly in its neuro product lines, versus 18% at top-quartile contract manufacturers.
Allocators should track two follow-on moves. First, whether KKR carves out Integer's legacy orthopedic battery business (roughly $180 million in revenue, declining 4% annually) within 12-18 months to focus capital on cardiac and neuro. Second, watch for add-on acquisitions in Europe, where Integer has 11% share versus 34% in North America—KKR's healthcare infrastructure fund has $2.1 billion in dry powder and a stated focus on medical supply chain consolidation. Timing matters: if the FDA's draft guidance on cybersecurity for implantables lands in Q1 2026 as expected, the compliance burden will push smaller component shops toward exit, and KKR will be the natural buyer.
Integer's Q3 2025 earnings call, scheduled for November 12, will be the last as a public company. The CEO noted in the deal announcement that the firm had already turned down three inbound offers since 2023, waiting for a bid that valued the neuro pipeline at replacement cost, not market comps. KKR paid it.